EG00229

CAS No. 1210945-69-9

EG00229( —— )

Catalog No. M32904 CAS No. 1210945-69-9

EG00229 is a neuropilin 1 (NRP1) receptor antagonist that selectively inhibits the binding of VEGF-A to the NRP1 b1 domain with an IC50 value of 3 μM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 68 Get Quote
5MG 96 Get Quote
10MG 151 Get Quote
25MG 244 Get Quote
50MG 361 Get Quote
100MG 525 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    EG00229
  • Note
    Research use only, not for human use.
  • Brief Description
    EG00229 is a neuropilin 1 (NRP1) receptor antagonist that selectively inhibits the binding of VEGF-A to the NRP1 b1 domain with an IC50 value of 3 μM.
  • Description
    EG00229 is a neuropilin 1 (NRP1) receptor antagonist. EG00229 selectively inhibits VEGF-A binding to NRP1 b1 domain with anIC50 of 3 μM, but has no effect on VEGFA binding to VEGFR-1 and VEGFR-2.
  • In Vitro
    EG00229 (Compound 2; 0-100 μM; 48 hours; A549 cells) treatment causes a significant reduction in cell viability over a 48 hours incubation.?EG00229 (Compound 2) demonstrates inhibition of VEGF-A binding to NRP1 and attenuates VEGFR2 phosphorylation in endothelial cells. Inhibition of migration of endothelial cells is also observed in HUVECs.EG00229 (Compound 2) selectively inhibits radiolabeled 125I-VEGF-A binding to porcine aortic endothelial (PAE)/NRP1, but not VEGFR2-expressing cells, with an IC50 of 8 μM. EG00229 also inhibits VEGF-A binding to lung carcinoma A549 and prostate carcinoma DU145 cells, which express NRP1, but not VEGFR1 and VEGFR2, with similar potency. Binding of VEGF-A to human umbilical vein endothelial cells (HUVECs), which express VEGFR2, VEGFR1, and NRP1, is also inhibited by EG00229 with an IC50 of 23 μM.Cell Viability Assay Cell Line:A549 cells Concentration:0 μM, 10 μM, 30 μM, 100 μM Incubation Time:48 hours Result:Caused a significant reduction in cell viability.
  • In Vivo
    EG00229 (0-10 mg/kg; intraperitoneal injection; three times per week; for 4 weeks; NSG mice) treatment substantially reduces tumor growth and visible vascularization.Animal Model:6-week old female NOD scid IL2 receptor gamma chain knockout mice (NSG mice) with ECS cells Dosage:0 mg/kg, 10 mg/kg Administration:Intraperitoneal injection; three times per week; for 4 weeks Result:Reduces tumor growth and visible vascularization.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1210945-69-9
  • Formula Weight
    611.6
  • Molecular Formula
    C19H20F3N7O7S3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : ≥ 41.4 mg/mL (67.69 mM)
  • SMILES
    OC(=O)C(F)(F)F.NC(=N)NCCC[C@H](NC(=O)c1sccc1NS(=O)(=O)c1cccc2nsnc12)C(O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Jarvis A, et al. Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction. J Med Chem. 2010 Mar 11;53(5):2215-26.?
molnova catalog
related products